Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 19, 2025

BUY
$18.17 - $20.92 $54,510 - $62,760
3,000 New
3,000 $54,000
Q2 2025

Dec 18, 2025

BUY
$17.1 - $21.8 $47,880 - $61,040
2,800 Added 1400.0%
3,000 $60,000
Q1 2025

Dec 18, 2025

SELL
$17.21 - $18.98 $48,188 - $53,144
-2,800 Reduced 93.33%
200 $3,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.55B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Danske Bank A/S Portfolio

Follow Danske Bank A/S and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

News

Stay updated on Danske Bank A/S with notifications on news.